In This Article:
LUXEMBOURG, March 26, 2025--(BUSINESS WIRE)--Regulatory News:
Eurofins Scientific (EUFI.PA, rated Baa3 by Moody’s and BBB- by Fitch) (Paris:ERF), a global leader in bioanalytical testing, announces today:
-
its intention to issue a new Euro-denominated hybrid bond for an amount of €400m ("New Hybrid Bond")
and
-
the launch of tender offer (the "Tender Offer") to repurchase its €400m 3.250% hybrid bond (ISIN: XS1716945586) issued on 13 November 2017 with a first call date of 13 November 2025 ("2025 Hybrid Bond")
The Tender Offer is subject to the success of the issuance of the New Hybrid Bond. Any 2025 Hybrid Bond validly tendered will be accepted for repurchase.
Results of the Tender Offer are expected to be announced on 03 April 2025 (subject to change as a result of any extension, withdrawal, termination or amendment of the Tender Offer).
The purpose of the Tender Offer and the planned issuance of the New Hybrid Bond is to proactively manage the refinancing of Eurofins' outstanding hybrid instruments and to increase the average life of its financing instruments.
Notes to Editors:
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. The Eurofins Scientific S.E. network of independent companies believes that it is a global leader in food, environment, pharmaceutical and cosmetic product testing and in discovery pharmacology, forensics, advanced material sciences and agroscience contract research services. It is also one of the market leaders in certain testing and laboratory services for genomics, and in the support of clinical studies, as well as in biopharma contract development and manufacturing. It also has a rapidly developing presence in highly specialised and molecular clinical diagnostic testing and in-vitro diagnostic products.
With ca. 63,000 staff across a decentralised and entrepreneurial network of more than 950 laboratories in over 1,000 companies in 60 countries, Eurofins offers a portfolio of over 200,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services and in-vitro diagnostic products.
Eurofins companies’ broad range of services are important for the health and safety of people and our planet. The ongoing investment to become fully digital and maintain the best network of state-of-the-art laboratories and equipment supports our objective to provide our customers with high-quality services, innovative solutions and accurate results in the best possible turnaround time (TAT). Eurofins companies are well positioned to support clients’ increasingly stringent quality and safety standards and the increasing demands of regulatory authorities as well as the evolving requirements of healthcare practitioners around the world.